Navigation Links
China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option
Date:12/31/2009

HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the underwriters of its recent public offering of common stock have exercised a portion of their over-allotment option, which will result in the issuance of an additional 314,867 ordinary shares. The option was granted in connection with the public offering of 3,305,786 ordinary shares at a public offering price of $6.05 per share, which closed on November 24, 2009. The closing of the over-allotment issuance is scheduled for Tuesday, January 5, 2010 and will bring the total gross proceeds of the public offering to $21.9 million. China Cord Blood Corporation intends to use the net proceeds from the offering for the expansion into new geographical markets, including applications for new licenses and acquisitions and investments, and for the construction and upgrading of facilities in existing geographical markets.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. ( RODM) acted as lead Manager of the offering and Macquarie Capital acted as co-manager for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering has been conducted solely by means of a prospectus supplement and accompanying prospectus relating to the offering of common stock can be obtained by contacting Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, NY 10020, or by calling 212-430-1710. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses have been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information about China Cord Blood Corporation, please visit: http://www.chinacordbloodcorp.com.

Forward-looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.


    For more information, please contact:
    China Cord Blood Corporation
    Ms. Joeling Law
    Phone: +852-3605-8180
    Email: ir@chinacordbloodcorp.com

    ICR, Inc.
    In the United States:
    Ashley M. Ammon or Christine Duan
    Phone: +1-646-277-1227
    In China:
    Wei-Jung Yang
    Phone: +86-10-6599-7968

SOURCE China Cord Blood Corporation

RELATED LINKS
http://www.chinacordbloodcorp.com

'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
2. American Oriental Bioengineering Announces the Inclusion of 158 Drugs in Chinas National Insurance Catalog
3. China Sky Medical, Inc. Has 30 Medicines that will Be Included in Chinas National Insurance Directory
4. China Biologic Products to Ring NASDAQ Opening Bell
5. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
6. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
7. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
8. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
9. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
10. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
11. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading ... to the North American healthcare market. , Aerocom Healthcare, LLC will be based ... company will provide new pneumatic tube systems or expand existing systems within the ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):